Cote d'Ivoire vs Mus: Previously treated cases tested for RR-/MDR-TB (%)
Cote d'Ivoire
100.0%
in 2024
Mus
100.0%
in 2022
Cote d'Ivoire rank
1st
Mus rank
1st
Previously treated cases tested for RR-/MDR-TB (%) over time
- Cote d'Ivoire
- Mus
How they compare
Cote d'Ivoire currently reports 100.0% against 100.0% in Mus, a difference of 0.0%.
The two have swapped places 2 times across 15 shared years of data; in 2005 it was Mus ahead.
Cote d'Ivoire ranks 1st and Mus ranks 1st of 180 countries.
Mus has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Cote d'Ivoire | Mus | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 8.6% | 86.7% | 78.1% | Mus |
| 2010s | 60.3% | 95.6% | 35.3% | Mus |
| 2020s | 100.0% | 100.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Cote d'Ivoire or Mus?
- Cote d'Ivoire, at 100.0% against 100.0% in Mus as of 2024.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Cote d'Ivoire and Mus?
- 0.0%, with Cote d'Ivoire ahead.
- How many years of comparable data are there for Cote d'Ivoire and Mus?
- 15 years are reported by both, from 2005 to 2022.
- How do Cote d'Ivoire and Mus rank globally for previously treated cases tested for rr-/mdr-tb?
- Cote d'Ivoire ranks 1st and Mus ranks 1st of 180 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.